Scarica l'app Stockscreener
37.61
2.74%
1.08
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$36.53
Aprire:
$37.82
Volume 24 ore:
624.93K
Relative Volume:
0.78
Capitalizzazione di mercato:
$764.23M
Reddito:
$90.12M
Utile/perdita netta:
$-276.06M
Rapporto P/E:
-25.76
EPS:
-1.46
Flusso di cassa netto:
$-193.47M
1 W Prestazione:
-0.40%
1M Prestazione:
-15.59%
6M Prestazione:
+50.12%
1 anno Prestazione:
+4,095%
Intervallo 1D:
$36.72
$39.75
Intervallo di 1 settimana:
$35.02
$39.75
Portata 52W:
$0.432
$66.92
Nektar Therapeutics Stock (NKTR) Company Profile
Nome
Nektar Therapeutics
Settore
Industria
Telefono
(415) 482-5300
Indirizzo
455 MISSION BAY BOULEVARD SOUTH, SAN FRANCISCO, CA
Confronta NKTR con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
NKTR
Nektar Therapeutics
|
37.57 | 743.08M | 90.12M | -276.06M | -193.47M | -1.46 |
|
VRTX
Vertex Pharmaceuticals Inc
|
463.69 | 118.58B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
749.62 | 79.40B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
813.59 | 51.18B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
360.48 | 48.88B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
339.19 | 37.49B | 4.98B | 69.59M | 525.67M | 0.5197 |
Nektar Therapeutics Stock (NKTR) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-11-26 | Iniziato | Citigroup | Buy |
| 2025-06-24 | Reiterato | BTIG Research | Buy |
| 2025-06-24 | Reiterato | H.C. Wainwright | Buy |
| 2025-04-11 | Aggiornamento | Jefferies | Hold → Buy |
| 2025-03-14 | Aggiornamento | Oppenheimer | Perform → Outperform |
| 2025-01-08 | Iniziato | B. Riley Securities | Buy |
| 2024-12-10 | Iniziato | H.C. Wainwright | Buy |
| 2024-11-04 | Iniziato | Piper Sandler | Overweight |
| 2024-09-30 | Ripresa | BTIG Research | Buy |
| 2024-06-28 | Iniziato | Rodman & Renshaw | Buy |
| 2023-11-20 | Ripresa | JP Morgan | Underweight |
| 2023-11-09 | Aggiornamento | TD Cowen | Market Perform → Outperform |
| 2023-05-10 | Aggiornamento | Jefferies | Underperform → Hold |
| 2023-02-24 | Downgrade | Jefferies | Hold → Underperform |
| 2022-08-08 | Downgrade | JP Morgan | Neutral → Underweight |
| 2022-05-31 | Ripresa | Jefferies | Hold |
| 2022-04-18 | Downgrade | Goldman | Neutral → Sell |
| 2022-03-15 | Downgrade | Cowen | Outperform → Market Perform |
| 2022-03-15 | Downgrade | Mizuho | Buy → Neutral |
| 2022-03-14 | Downgrade | BTIG Research | Buy → Neutral |
| 2022-03-14 | Downgrade | BofA Securities | Neutral → Underperform |
| 2022-03-14 | Downgrade | Stifel | Buy → Hold |
| 2022-03-14 | Downgrade | William Blair | Outperform → Mkt Perform |
| 2022-03-09 | Aggiornamento | Oppenheimer | Perform → Outperform |
| 2021-11-08 | Aggiornamento | The Benchmark Company | Hold → Buy |
| 2021-09-10 | Iniziato | BofA Securities | Neutral |
| 2021-06-28 | Aggiornamento | Stifel | Hold → Buy |
| 2021-05-18 | Ripresa | Goldman | Neutral |
| 2021-02-22 | Downgrade | The Benchmark Company | Buy → Hold |
| 2021-01-06 | Iniziato | Stifel | Hold |
| 2020-09-14 | Iniziato | JP Morgan | Neutral |
| 2020-06-10 | Downgrade | CFRA | Hold → Sell |
| 2020-05-12 | Reiterato | H.C. Wainwright | Neutral |
| 2020-04-22 | Iniziato | The Benchmark Company | Buy |
| 2020-03-30 | Aggiornamento | Goldman | Sell → Neutral |
| 2020-03-04 | Iniziato | Barclays | Overweight |
| 2020-02-03 | Aggiornamento | Mizuho | Neutral → Buy |
| 2019-10-24 | Iniziato | Oppenheimer | Perform |
| 2019-10-08 | Downgrade | Goldman | Buy → Sell |
| 2019-08-09 | Downgrade | JP Morgan | Overweight → Neutral |
| 2019-08-09 | Downgrade | Jefferies | Buy → Hold |
| 2019-08-09 | Downgrade | Mizuho | Buy → Neutral |
| 2019-03-15 | Iniziato | SVB Leerink | Mkt Perform |
| 2018-12-13 | Iniziato | Goldman | Buy |
| 2018-06-11 | Downgrade | H.C. Wainwright | Buy → Neutral |
| 2018-06-04 | Reiterato | H.C. Wainwright | Buy |
| 2018-04-20 | Iniziato | Seaport Global Securities | Buy |
| 2018-04-13 | Ripresa | Piper Jaffray | Overweight |
| 2018-04-06 | Reiterato | Mizuho | Buy |
| 2018-04-02 | Ripresa | H.C. Wainwright | Buy |
Mostra tutto
Nektar Therapeutics Borsa (NKTR) Ultime notizie
Emerald Mutual Fund Advisers Trust Invests $13.27 Million in Nektar Therapeutics $NKTR - MarketBeat
Insider Sell: Jonathan Zalevsky Sells Shares of Nektar Therapeutics - GuruFocus
Nektar Therapeutics (NASDAQ:NKTR) Insider Sells $137,935.89 in Stock - MarketBeat
Nektar Therapeutics’ chief R&D officer sells $137,935 in stock - Investing.com
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Nektar TherapeuticsNKTR - PR Newswire
Emerald Advisers LLC Takes Position in Nektar Therapeutics $NKTR - MarketBeat
NK Cell Therapy Market 2034: 7MM Outlook, 30+ Active Developers, IND/NDA Momentum, and Next-Gen CAR-NK Innovations Driving Immunotherapy Advances | DelveInsight - Barchart.com
Nektar Therapeutics Q3 Loss Narrower Than Expected, Revenues Rise Y/Y - MSN
What Recent Price Target Signals For The Evolving Nektar Therapeutics (NKTR) Story - Yahoo Finance
Nektar Therapeutics: Share Price Dislocation Masks Rezpeg’s Underappreciated Atopic Dermatitis and Alopecia Areata Upside - TipRanks
Corvus pill shows promise in early-stage eczema trial - statnews.com
Bond Watch: Should I buy Nektar Therapeutics stock nowJuly 2025 Technicals & Daily Profit Maximizing Trade Tips - baoquankhu1.vn
Aug Fed Impact: Should I buy Nektar Therapeutics stock nowMarket Performance Report & Free Community Consensus Stock Picks - baoquankhu1.vn
Nektar Therapeutics Stock Defies Short Sellers with Sharp Rally - AD HOC NEWS
Nektar Therapeutics’ Earnings Call Highlights Robust Growth and Innovation - MSN
Short Interest in Nektar Therapeutics (NASDAQ:NKTR) Rises By 52.3% - MarketBeat
Nektar Therapeutics (NASDAQ:NKTR) Trading Up 6.9%Still a Buy? - MarketBeat
Nektar Therapeutics (NASDAQ:NKTR) Stock Price Down 6.7%What's Next? - MarketBeat
History Review: Is Nektar Therapeutics stock a value trapTrade Entry Summary & Reliable Entry Point Trade Alerts - baoquankhu1.vn
Why the JP Morgan conference is important — but not make-or-break - statnews.com
BTIG maintains Nektar Therapeutics (NKTR) buy recommendation - MSN
Ignore Nektar Therapeutics stock in 2026 and load up on this one instead - MSN
Will Nektar Therapeutics (ITH0) stock outperform energy sector in 2025Trade Performance Summary & Step-by-Step Trade Execution Guides - ulpravda.ru
Nektar Therapeutics (NKTR) price target increased by 14.31% to 109.43 - MSN
Q1 EPS Estimate for Nektar Therapeutics Raised by Analyst - MarketBeat
Nektar Therapeutics (NASDAQ:NKTR) Shares Pass Above 200 Day Moving AverageHere's What Happened - MarketBeat
Here's why Nektar Therapeutics (NKTR) is a great momentum stock to buy - MSN
Nektar leaps a third on abuse-deterrent analgesic data - The Pharma Letter
Why Nektar Therapeutics stock remains on watchlists2025 Macro Impact & Advanced Swing Trade Entry Alerts - ulpravda.ru
Can Nektar Therapeutics stock sustain institutional interestJuly 2025 Earnings & Accurate Intraday Trading Signals - ulpravda.ru
Why analysts remain bullish on Nektar Therapeutics stockTrend Reversal & Weekly High Return Stock Forecasts - ulpravda.ru
Is Nektar Therapeutics stock a dividend growth opportunity2025 Trade Ideas & Precise Trade Entry Recommendations - ulpravda.ru
Is Nektar Therapeutics stock a buy in volatile marketsJuly 2025 Market Mood & High Accuracy Trade Alerts - ulpravda.ru
Zacks Industry Outlook Highlights Soleno Therapeutics, Nektar Therapeutics, Rigel Pharmaceuticals, Ironwood Pharmaceuticals and Marker Therapeutics - Yahoo Finance
Nektar Therapeutics Shares Rise After Positive Asthma Data in Atopic Dermatitis Patients - MSN
Nektar promotions promised to drive growth of I-O pipeline - The Pharma Letter
Portfolio Shifts: Why Nektar Therapeutics ITH0 stock trades below fair valueJuly 2025 Trends & Expert Approved Trade Ideas - moha.gov.vn
Nektar TherapeuticsCommon Stock (NQ: NKTR - FinancialContent
How The Narrative Around Nektar Therapeutics (NKTR) Is Shifting With Rezpeg Data And Litigation Risks - Yahoo Finance
Nektar Therapeutics Too Risky? This Biotech Stock Offers a Safer Bet - NAI500
Ignore Nektar Therapeutics Stock in 2026 and Load Up on This One Instead - AOL.com
New anxiety medications are in the pipeline for 2026 - AOL.com
FDA Leadership Stability Urged as Rare Disease Drug Approval Policies Expected to Show Results by 2026 - geneonline.com
Nektar Therapeutics: Can a Beaten-Down Biotech Still Surprise Wall Street? - AD HOC NEWS
What drives Nektar Therapeutics stock priceFinancial Sector Performance & Free Unlock Portfolio Growth - earlytimes.in
How Nektar Therapeutics stock reacts to global recession fearsGrowth vs. Value Investing & Optimize Entry & Exit With Smart Signals - bollywoodhelpline.com
Drugs to Watch in 2026 - Dermatology Times
Nektar Therapeutics Stock Analysis and ForecastStock Screening Results & Outstanding Return Portfolio - earlytimes.in
Moody Aldrich Partners LLC Buys 28,304 Shares of Nektar Therapeutics $NKTR - MarketBeat
Nektar Therapeutics Azioni (NKTR) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
4.38%
1.95%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):